Substituted butenamide pharmaceutical composition and preparation method thereof
阅读说明：本技术 一种取代丁烯酰胺药物组合物及其制备方法 (Substituted butenamide pharmaceutical composition and preparation method thereof ) 是由 唐海涛 王蓓 葛滨 葛海涛 王正俊 于 2019-11-27 设计创作，主要内容包括：本发明属于药物制剂领域,涉及一种取代丁烯酰胺药物组合物及其制备方法,该药物组合物含有(E)-N-(3-氰基-7-乙氧基-4-(3-乙炔基苯基氨基)喹啉-6-基)-4-(二甲基氨基)丁-2-烯酰胺马来酸盐5～50份,填充剂40～120份,崩解剂2～20份,粘合剂0～6份,润滑剂0.5～5份,所述填充剂选自碳水化合物,该药物组合物具有质量稳定性好,适合大规模生产的有益效果。(The invention belongs to the field of pharmaceutical preparations, and relates to a substituted butenamide pharmaceutical composition and a preparation method thereof, wherein the pharmaceutical composition contains 5-50 parts of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide maleate, 40-120 parts of a filler, 2-20 parts of a disintegrant, 0-6 parts of an adhesive and 0.5-5 parts of a lubricant, and the filler is selected from carbohydrates.)
1. A pharmaceutical composition of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or a salt thereof, characterized by comprising the following components in parts by weight: (E) 5-50 parts of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or salt thereof, 40-120 parts of filler, 2-20 parts of disintegrant, 0-6 parts of adhesive and 0.5-5 parts of lubricant.
2. The pharmaceutical composition according to claim 1, characterized by comprising the following components in parts by weight: (E) 8-12 parts of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enoyl or a salt thereof, 50-100 parts of a filler, 4-15 parts of a disintegrant, 0.3-5 parts of a binder and 0.3-6 parts of a lubricant.
3. The pharmaceutical composition according to claim 1, characterized by comprising the following components in parts by weight: (E) 9-11 parts of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or salt thereof, 65-90 parts of filler, 5-12 parts of disintegrant, 0.5-3 parts of adhesive and 0.5-4 parts of lubricant.
4. Pharmaceutical composition according to any one of claims 1 to 3, characterized in that the bulking agent is selected from carbohydrates, preferably sugar compounds, even more preferably sugar alcohols.
5. Pharmaceutical composition according to any one of claims 1 to 3, characterized in that the sugar alcohol is mannitol, xylitol, sorbitol, lactose, more preferably one or more of mannitol, lactose.
6. The pharmaceutical composition according to any one of claims 1 to 3, characterized in that the disintegrant is one or both of sodium carboxymethyl starch, croscarmellose sodium, preferably sodium carboxymethyl starch.
7. The pharmaceutical composition according to any one of claims 1 to 3, characterized in that the binder is one or both of hydroxypropyl cellulose or hypromellose, preferably hydroxypropyl cellulose; still further, the lubricant is one or more of glyceryl behenate, sodium stearyl fumarate and talcum powder, and glyceryl behenate is preferred.
8. The pharmaceutical composition according to any one of claims 1 to 3, characterized in that the salt is a hydrochloride, benzenesulfonate, methanesulfonate or maleate salt, further a hemihydrate, monohydrate, preferably a maleate monohydrate, of a hydrochloride, benzenesulfonate, methanesulfonate or maleate salt; preferably, the moisture content of the pharmaceutical composition is within 5% or 3% or 1.5%.
9. Process for the preparation of a pharmaceutical composition according to any one of claims 1 to 8, characterized in that it comprises the following steps:
(1) premixing: uniformly mixing (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide maleate, a filling agent and a disintegrating agent;
(2) and (3) wet granulation: adding binder solution to make soft mass, sieving, granulating, and making into wet granule
(3) Drying, finishing and total mixing: drying the wet granules, sieving, grading, adding a lubricant, and mixing to obtain the pharmaceutical composition.
10. The preparation method of the pharmaceutical composition according to claim 9, wherein the adhesive in step (2) is prepared from purified water, and the concentration of the adhesive is 2-10%; controlling the moisture of the dried particles in the step (3) within 1.5%, preferably within 1%.
Technical Field
The invention belongs to the field of pharmaceutical preparations, and particularly relates to a substituted butenamide pharmaceutical composition and a preparation method thereof.
Background
Lung cancer is the most common malignancy with the highest incidence and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for about 80% of all lung cancers. The highest incidence of non-small cell lung cancer is adenocarcinoma. Currently, adenocarcinoma has found driver mutations, including EGFR, ALK, ROS1 mutations. The survival time of the target medicine used aiming at the mutant gene is obviously improved compared with the chemotherapy medicine used in the past. The targeted medicament for treating the gene-mutated non-small cell lung cancer has the effective rate of over 70 percent, the time for controlling the tumor is twice of that of chemotherapy, and the targeted medicament has small side effect and high life quality.
The epidermal growth factor receptor tyrosine kinase inhibitors EGFR-TKIs have good treatment effect on NSCLC patients with EGFR gene sensitive mutation, and first-line treatment by using EGFR-TKI is standard treatment. EGFR-TKIs include first generation gefitinib, erlotinib, second generation dacomitinib, afatinib, and third generation axitinib. The effects of inhibiting tumor growth are achieved by blocking EGFR tyrosine kinase phosphorylation activation signals and downstream MAPK and AKT signal pathways in cancer cells, inhibiting proliferation, promoting apoptosis, resisting tumor angiogenesis and the like.
Substituted crotonamide compound (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or a salt thereof is EGFR-TKIs suitable for non-small cell lung cancer, (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide maleate, also named (E) -N- {4- [ (3-ethynylphenylamino) -3-cyano-7-ethoxy-6-quinolinyl ] } -4- (dimethylamino) -2-butenamide A maleate salt. The structural formula is shown as the following formula (1):
(E) the raw material of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or the salt thereof is sensitive to damp heat, and generates related impurity A shown as a structural formula (2) under damp heat conditions.
There is no prior art describing the control or inhibition of the production of impurity a of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or a salt thereof by means of a formulation composition.
Disclosure of Invention
The technical problem to be solved by the invention is to provide a pharmaceutical composition of a substituted crotonamide compound (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or a salt thereof, wherein the pharmaceutical composition has good stability.
In one aspect of the present invention, there is provided a pharmaceutical composition of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or a salt thereof, comprising the following components in parts by weight: (E) 5-50 parts of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or salt thereof, 40-120 parts of filler, 2-20 parts of disintegrant, 0-6 parts of adhesive and 0.5-5 parts of lubricant.
The composition further comprises 8-12 parts of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enoyl or a salt thereof, 50-100 parts of a filler, 4-15 parts of a disintegrant, 0.3-5 parts of an adhesive and 0.3-6 parts of a lubricant. Further comprising 9 to 11 parts of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or a salt thereof, 65 to 90 parts of a filler, 5 to 12 parts of a disintegrant, 0.5 to 3 parts of a binder, and 0.5 to 4 parts of a lubricant. More specifically, (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or salt thereof 10 parts, a filler 65-90 parts, a disintegrant 5-12 parts, a binder 0.5-3 parts, and a lubricant 0.5-4 parts.
The bulking agent is selected from carbohydrates, preferably saccharides, and more preferably sugar alcohols. The sugar alcohol is selected from one or more of mannitol, xylitol, sorbitol and lactose, and more preferably one or more of mannitol and lactose.
The disintegrating agent is one or two of sodium carboxymethyl starch and croscarmellose sodium, preferably sodium carboxymethyl starch.
The adhesive is one or two of hydroxypropyl cellulose or hydroxypropyl methylcellulose, and preferably hydroxypropyl cellulose.
The lubricant is one or more of glyceryl behenate, sodium stearyl fumarate and pulvis Talci, preferably glyceryl behenate.
The salt of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enoyl is a pharmaceutically acceptable salt.
The pharmaceutically acceptable salts include those salts commonly used to form alkali metal salts and to form addition salts of the free acids or free bases approved by regulatory agencies. Salts are formed by ionic association, charge-charge interaction, covalent bonding, complexation, coordination, and the like. The nature of the salt is not critical as long as it is pharmaceutically acceptable.
The types of pharmaceutically acceptable salts include, but are not limited to, the acid addition salts formed by reacting the free base form of the compound with the following pharmaceutically acceptable acids: inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and the like; or organic acids such as acetic, propionic, glycolic, pyruvic, lactic, malonic, succinic, malic, maleic, fumaric, tartaric, citric, methanesulfonic, benzenesulfonic, toluenesulfonic, gluconic, glutamic, hydroxynaphthoic, salicylic acid and the like.
Other examples of such salts can be found in Berge et al, j.pharm.sci, 66, 1 (1977). In some embodiments, the salt is formed using conventional methods. For example, the phosphate salts of the compounds of the present invention are prepared by mixing the desired free base of the compound in the desired solvent or combination of solvents with the desired stoichiometric amount of phosphoric acid at the desired temperature, usually under heating (depending on the boiling point of the solvent). In one embodiment, the salt precipitates and crystallizes (i.e., if crystalline in nature) upon cooling (slowly or rapidly). In addition, the hemi-, mono-, di-, tri-and poly-salt forms of the compounds of the present invention are also included herein. Similarly, the compounds, salts or hemihydrate, monohydrate, dihydrate, trihydrate and polyhydrate forms thereof are also included herein.
In some embodiments, the compound is a hydrochloride, hydrobromide, sulfate, phosphate or metaphosphate, acetate, propionate, hexanoate, cyclopentanepropionate, glycolate, pyruvate, lactate, malonate, succinate, malate, maleate, fumarate, trifluoroacetate, tartrate, citrate, benzoate, 3- (4-hydroxybenzoyl) benzoate, cinnamate, mandelate, methanesulfonate, ethanesulfonate, 1, 2-ethanedisulfonate, 2-hydroxyethanesulfonate, benzenesulfonate, toluenesulfonate, 2-naphthalenesulfonate, 4-methylbicyclo- [2.2.2] oct-2-ene-1-carboxylate, glucoheptonate, 4' 4-methylenebis- (3-hydroxy-2-ene-1-carboxylic acid) salt, glucoheptonate, or salt, 3-phenylpropionate, pivalate, t-butyl acetate, lauryl sulfate, gluconate, glutamate, hydroxynaphthoate, salicylate, stearate, muconate, butyrate, phenylacetate, phenylbutyrate, valproate, and the like.
In a preferred embodiment, the salt of the compound is a hydrochloride, benzenesulfonate, methanesulfonate, maleate, or a hydrate thereof, e.g., a monohydrate. In particular, (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enylmaleate and its monohydrate are particularly suitable.
The water content of the pharmaceutical composition of the present invention is preferably 5% or less, more preferably 3% or less, still more preferably 2% or 1.5% or less, and particularly preferably 1% or less.
The pharmaceutical composition of the present invention may further comprise pharmaceutically acceptable excipients, including but not limited to carriers, excipients, binders, fillers, suspending agents, flavoring agents, sweeteners, disintegrants, dispersants, surfactants, lubricants, colorants, diluents, solubilizers, wetting agents, plasticizers, stabilizers, permeation enhancers, wetting agents, antifoaming agents, antioxidants, preservatives, or a combination of one or more thereof. The pharmaceutical composition facilitates administration of the compound to an organism.
The pharmaceutical compositions of the present invention may be further formulated into pharmaceutical formulations for convenient administration to a patient, including, but not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, disintegrating (fastmelt) formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate release and controlled release formulations.
In another aspect of the present invention, there is provided a method for preparing the pharmaceutical composition of E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or a salt thereof, comprising the steps of:
(1) premixing: mixing (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or salt thereof, a filler and a disintegrant;
(2) and (3) wet granulation: adding binder solution to make soft mass, sieving, and granulating to obtain wet granule;
(3) drying, finishing and total mixing: drying the wet granules, sieving, grading, adding a lubricant, and mixing to obtain the pharmaceutical composition. The pharmaceutical composition can be further tableted into tablets, or encapsulated into capsules. Wherein the premixing mode in the step (1) comprises air flow crushing premixing, sieving premixing and wet granulating machine premixing; the adhesive in the step (2) is prepared from purified water, and the concentration of the adhesive is 2-10%; the wet granulation in the step (2) can be carried out by adopting a wet granulator or a fluidized bed, and preferably, the granulation and drying of the fluidized bed are carried out; the drying in the step (3) can be carried out by adopting forced air drying or a fluidized bed, and the fluidized bed is preferred; the moisture content of the dried granules is controlled to be within 1.5%, preferably within 1%.
The present invention provides another method for preparing a pharmaceutical composition of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or a salt thereof, comprising the steps of:
(1) premixing: mixing the active ingredients with filler and disintegrant
(2) Drying and total mixing: and adding a lubricant into the dried powder for total mixing. Wherein the pre-powdering mode in the step (1) comprises air flow crushing and premixing, sieving and premixing and wet granulating machine premixing; the drying in the step (2) can be carried out by adopting forced air drying, and the moisture after drying is controlled within 3 percent or 1.5 percent, preferably within 1 percent.
Specifically, in the preparation process of the pharmaceutical composition, maleic acid (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or salt thereof is uniformly mixed with a filler and a disintegrating agent, then an adhesive solution is added to prepare a soft material, then granulation and drying are carried out, the moisture of the dried granules is controlled within 3% or 1.5%, finally a lubricant is added to the mixture to prepare the pharmaceutical composition, and other pharmaceutically acceptable auxiliary materials can be added to the pharmaceutical composition to prepare a pharmaceutical preparation such as a tablet or a capsule. Or uniformly mixing the active component maleic acid (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide or the salt thereof with a filling agent and a disintegrating agent, then adding a lubricating agent, totally mixing, drying, controlling the moisture content within 3% or 1.5% after drying, and preparing the pharmaceutical composition, wherein the pharmaceutical composition can be added with other pharmaceutically acceptable auxiliary materials to prepare a pharmaceutical preparation such as a tablet or a capsule.
More specifically, the preferred preparation method of the pharmaceutical composition of the present invention comprises the following steps:
(1) premixing: mixing the active ingredient, filler and disintegrant;
(2) and (3) wet granulation: adding a binder solution to prepare a soft material, and granulating with a 20-30-mesh sieve;
(3) drying, finishing and total mixing: and drying the wet granules, sieving the dried wet granules by a 0-30-mesh sieve, grading the granules, adding a lubricant, and mixing to obtain the pharmaceutical composition.
The invention has the beneficial effects that:
the pharmaceutical composition of the invention greatly improves the fluidity of materials, solves the problems of difficult preparation, low finished product content and related substance increase caused by the fact that the raw materials have high viscosity and are easy to adhere to the wall of a container, and has good quality with good quality stability.
Detailed Description
The pharmaceutical composition of (E) -N- (3-cyano-7-ethoxy-4- (3-ethynylphenylamino) quinolin-6-yl) -4- (dimethylamino) but-2-enamide maleate monohydrate (hereinafter referred to as active ingredient) and the process for its preparation according to the present invention are further illustrated by the following examples, which are not intended to limit the invention in any way. The active ingredient is prepared according to the method described in CN 104513200A.
Example 1
Composition of single dose prescription
Composition (I)
Single dose (mg)
Active ingredient
20
Mannitol
120
Microcrystalline cellulose
35
Cross-linked polyvidone
7
Povidone K30
5
Magnesium stearate
1
Colloidal silica
5
Total up to
193
Adding the active ingredients, mannitol, microcrystalline cellulose and crospovidone according to the formula amount into a wet granulator, uniformly mixing, preparing a soft material by taking 15% of povidone K30 as an adhesive, sieving with a 20-mesh sieve, granulating, and drying, wherein the moisture of the granules is controlled within 1.5%. After finishing the granules with 10 meshes, adding magnesium stearate and colloidal silicon dioxide with the prescription amount into the granules, and after the mixture is totally mixed, filling the intermediate granules into capsules.
Example 2
Composition of single dose prescription
Composition (I)
Single dose (mg)
Active ingredient
20
Microcrystalline cellulose
170
Povidone K30
10
Glyceryl behenate
4
Colloidal silica
2
Total up to
196
Adding the active ingredients and microcrystalline cellulose in the formula amount into a wet granulator, uniformly mixing, preparing a soft material by taking 15% of povidone K30 as an adhesive, sieving with a 20-mesh sieve, granulating, and drying, wherein the moisture of the granules is controlled within 1.5%. And (3) after finishing the granules with 0-30 meshes, adding the behenic acid glyceride and the colloidal silicon dioxide in the formula amount, and after total mixing, performing capsule filling on the intermediate granules.
Example 3
Composition of single dose prescription
Composition (I)
Single dose (mg)
Active ingredient
20
Mannitol
170
Povidone K30
10
Glyceryl behenate
4
Colloidal silica
2
Total up to
196
Adding the active ingredients and mannitol into a wet granulator, uniformly mixing, preparing a soft material by taking 15% povidone K30 as an adhesive, sieving with a 20-mesh sieve, granulating, and drying, wherein the moisture of the granules is controlled within 1.5%. Adding the docosanoic acid glyceride and the colloidal silicon dioxide into the granules after finishing the granules, and filling the intermediate granules after total mixing into capsules.
Example 4
Composition of single dose prescription
Composition (I)
Single dose (mg)
Active ingredient
20
Mannitol
160
Sodium starch glycolate
10
Hydroxypropyl cellulose
1
Glyceryl behenate
4
Total up to
195
Adding the active ingredients, mannitol and carboxymethyl starch sodium in the formula amount into a wet granulator, uniformly mixing, preparing a soft material by using 4% hydroxypropyl cellulose as an adhesive, sieving with a 20-mesh sieve, granulating, and drying, wherein the moisture of the granules is controlled within 1.5%. Adding the glyceryl behenate into the granules after finishing the granules with 10 meshes, and filling the intermediate granules into capsules after total mixing.
The capsule granules of examples 1, 2, 3 and 4 were placed in an open weighing bottle and left at a high temperature of 40 ℃ for 1 month, and then taken out to be tested for the relevant substances, wherein the impurity A was tested according to the conventional C18 column liquid phase analysis method, and the results are as follows:
Time
example 1
Example 2
Example 3
Example 4
Day 0
0.08
0.07
0.05
0.04
14 days
0.15
0.32
0.12
0.08
1 month
0.24
0.46
0.26
0.14
The above results show that: the related substance of the composition of example 4, impurity a, increased slowly when left at high temperature for 1 month. The stability of the pharmaceutical composition prepared according to the technical scheme of the invention is obviously improved compared with other prescription compositions.
Example 5
Composition of single dose prescription
Composition (I)
Single dose (mg)
Active ingredient
20
Mannitol
200
Sodium starch glycolate
10
Hydroxypropyl cellulose
3
Glyceryl behenate
5
Total up to
238
Adding the active ingredients, mannitol and carboxymethyl starch sodium in the formula amount into a wet granulator, uniformly mixing, preparing a soft material by using 4% hydroxypropyl cellulose as an adhesive, sieving with a 20-mesh sieve, granulating, and drying to respectively obtain granules with the water content of 0.8%, 1.0% and 1.4%. And (3) adding the glyceryl behenate into each granule after finishing the granules respectively, and filling the intermediate granules into capsules after total mixing.
The capsule granules of example 5 containing different water contents were placed under accelerated conditions of 40 ℃ high temperature, 92.5% RH high humidity, 4500lux light (40 ℃ high temperature, 75% high humidity) for 14 days, and then taken out to measure the impurity A, which is a related substance, and the results are shown in the following table:
related substance (%)
0.8% moisture particles
1.0% moisture granules
1.4% moisture granules
Day 0
0.03
0.03
0.04
High temperature for 14 days
0.09
0.10
0.10
High humidity for 14 days
0.08
0.07
0.08
Illuminating for 14 days
0.07
0.08
0.08
Accelerating for 14 days
0.09
0.08
0.09
The above results show that: the preparation composition with the moisture of the granules within 1.5 percent is stable.
Example 6
Composition of single dose prescription
Composition (I)
Single dose (mg)
Active ingredient
20
Mannitol
160
Cross-linked polyvidone
10
Hydroxypropyl cellulose
1
Glyceryl behenate
4
Total up to
195
Adding the active ingredients, mannitol and crospovidone according to the formula amount into a wet granulator, uniformly mixing, preparing a soft material by taking 4% hydroxypropyl cellulose as an adhesive, sieving with a 20-mesh sieve, granulating, and drying, wherein the moisture of the granules is controlled within 1.5%. Adding the glyceryl behenate into the granules after finishing the granules, and filling the intermediate granules into capsules after total mixing.
Example 7
Composition of single dose prescription
Composition (I)
Single dose (mg)
Active ingredient
20
Mannitol
130
Sodium starch glycolate
20
Hydroxypropyl cellulose
1
Glyceryl behenate
1
Total up to
172
Adding the active ingredients, mannitol and carboxymethyl starch sodium in the formula amount into a wet granulator, uniformly mixing, preparing a soft material by taking 4% hydroxypropyl cellulose as an adhesive, sieving with a 20-mesh sieve, granulating, and drying, wherein the moisture of the granules is controlled within 1.5%. Adding the glyceryl behenate with the prescription amount, and filling the intermediate into capsules after total mixing.
Example 8
Composition of single dose prescription
Composition (I)
Single dose (mg)
Active ingredient
20
Lactose monohydrate
160
Sodium starch glycolate
10
Hydroxypropyl cellulose
1.5
Glyceryl behenate
8
Total up to
208.5
Adding the active ingredients, lactose monohydrate and carboxymethyl starch sodium in the formula amount into a wet granulator, uniformly mixing, preparing a soft material by taking 4% hydroxypropyl cellulose as an adhesive, sieving with a 20-mesh sieve, granulating, and drying, wherein the moisture of the granules is controlled within 1.5%. Adding the glyceryl behenate into the granules after finishing the granules, and filling the intermediate granules into capsules after total mixing.
The capsules of examples 1, 2, 3, 4, 6, 7 and 8 were packed in high density polyethylene bottles, 20 capsules/bottle, and desiccant was added into 2 bags/bottle, and the bottles were placed under accelerated conditions (40 ℃ C. and 75% humidity) for 3 months, and the change results of the content of impurity A in each lot are as follows:
impurity A (%)
Example 1
Example 4
Example 6
Example 7
Example 8
Day 0
0.08
0.04
0.09
0.05
0.06
Accelerating for 1 month
0.28
0.14
0.15
0.15
0.12
Accelerated for 2 months
0.48
0.20
0.25
0.21
0.18
Accelerated for 3 months
0.62
0.20
0.47
0.22
0.20
The above results show that: the capsules prepared according to the technical scheme of the invention have significantly improved stability when placed for 3 months under accelerated conditions, and the stability of the prescriptions in examples 4, 7 and 8 is significantly higher than that of the other prescriptions.